Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: December 2, 2014
Event: Entry into a Material Definitive Agreement to settle patent litigation and establish licensing arrangements regarding Non-Invasive Prenatal Testing (NIPT).
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial disclosure relates to a specific settlement payment.
- Settlement Payment: $50 million aggregate payment to Sequenom, Inc.
- Future Obligations: Agreement to pay royalties to Sequenom for sales of NIPT In-Vitro Diagnostic (IVD) products.
Material Changes and Agreements
The Company and its subsidiary Verinata Health, Inc. entered into a series of agreements with Sequenom, Inc., Sequenom Center for Molecular Medicine LLC, Chinese University of Hong Kong (CUHK), and Stanford University. Key terms include:
- Litigation Settlement: Resolved pending patent litigation in the U.S. District Court for the Northern District of California and an inter partes review regarding U.S. Patent No. 8,195,415.
- Patent Licensing:
- Sequenom grants Illumina a worldwide license for NIPT Laboratory Developed Testing (LDT) and IVD products (exclusive except for certain Isis-owned patents).
- Illumina grants Sequenom a worldwide non-exclusive license under Illumina-owned NIPT patents to continue its NIPT LDT business.
- Parties agreed to share licensing revenues for the exploitation of "Pooled Patents" in NIPT LDT.
- Supply and Data Transfer: Extended and amended the supply agreement for NIPT equipment; Sequenom will transfer clinical samples and data to Illumina for NIPT IVD development.
- Liability: No party made an admission of liability.
Guidance, Outlook, and Risks
Management Commentary: The settlement allows both parties to dismiss associated claims and counterclaims with prejudice. The Pooled Patents Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 28, 2014.
Risks and Contingencies: The filing notes that the description of the Pooled Patents Agreement is qualified in its entirety by reference to the full agreement. Future financial impact will depend on royalty payments tied to NIPT IVD product sales.
Investor Verification Checklist
- Verify the exact terms of the royalty payments for NIPT IVD products in the full Pooled Patents Agreement (to be filed in the 10-K).
- Confirm the status of the vacated and dismissed claims in the Federal Circuit and District Court.
- Assess the impact of the $50 million cash outflow on the Company's liquidity for the fiscal year ending December 28, 2014.
- Review the scope of the "Pooled Patents" to understand the competitive landscape for NIPT LDT and IVD.